3 reports

  • Synairgen Plc, Major Products and Services
  • Section 2 - Company Analysis Synairgen Plc - Business Description

Synairgen Plc (SNG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The...

  • Pharmaceutical
  • Respiratory Disease
  • World
  • Company Financials
  • Synairgen plc
  • ASTRAZENECA ENTERS INTO LICENSING AGREEMENT WITH SYNAIRGEN FOR SNG001
  • Clinical Trials

It targets interferon alpha receptor ## and ##.

  • Chronic Disease
  • Healthcare
  • Pharmaceutical
  • United Kingdom
  • Synairgen plc
  • A Wright Investors' Service Research Report:
  • Summary of company valuations (as of 3/16/2018).

Its drug programs include IFN-b (SNG##) for Asthma and COPD, and Lysyl oxidase-like protein ## (LOXL##) inhibitors for IPF.

  • United States
  • World
  • Company Financials
  • Synairgen plc